RxDoctor Payments Data

Maria Theresa Browne, MD

Family Medicine · Brighton, MINPI 1306870415

Payments from drug & device makers

$2,154in general payments, 2019–2025

Across 124 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$381
  • AstraZeneca$358
  • Lilly USA, LLC$245
  • GSK$209
  • Pfizer$189
  • Sumitomo Pharma America, Inc.$127
  • plus $645 from 13 others

What the payments were for

  • Food & beverage$2,07997%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,154 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$67,797
Medicare patients
200
Services billed
953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$99,882
OzempicSemaglutide51$75,163
JardianceEmpagliflozin46$60,371
FarxigaDapagliflozin Propanediol47$57,272
XareltoRivaroxaban48$50,710
JanuviaSitagliptin Phosphate33$44,908
RybelsusSemaglutide26$36,991
MyrbetriqMirabegron45$34,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$27,452
MounjaroTirzepatide21$20,848
GemtesaVibegron23$18,876
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$14,922
Atorvastatin Calcium736$10,994
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$9,503
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$8,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$381$112,15477 claims
PfizerEliquis, Paxlovid$189$102,663109 claims
AstraZenecaFarxiga, Breztri Aerosphere$358$66,23562 claims
Boehringer IngelheimJardiance$19$60,37146 claims
Johnson & JohnsonXarelto$15$50,71048 claims
MerckJanuvia$48$44,90833 claims
Astellas Pharma US IncMyrbetriq$87$34,36345 claims
GSKTrelegy Ellipta$209$27,45226 claims
Lilly USA, LLCMounjaro$245$20,84821 claims
Sumitomo Pharma America, Inc.Gemtesa$127$18,87623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Brighton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →